Dates: September 14-18, 2026
Location: Barcelona International Convention Centre, Spain
Organizer: World Parkinson Congress Board
Website: worldparkinsoncongress.org
The World Parkinson Congress (WPC) is the only international conference focused exclusively on Parkinson's disease and movement disorders. The congress brings together people with Parkinson's, care partners, healthcare professionals, researchers, and industry stakeholders in a unique, multidisciplinary setting.
WPC 2026 marks the return of this prestigious event to Barcelona, following previous successful editions. The congress emphasizes the voice of people living with Parkinson's and fosters dialogue between all stakeholders in the Parkinson's community.
- Living Well with Parkinson's: Quality of life, care strategies, and patient empowerment
- Research Advances: Basic science, clinical trials, and therapeutic development
- Care and Support: Healthcare delivery, support services, and caregiver resources
- Innovation: Technology, digital health, and emerging therapies
- Plenary Sessions: Major presentations from leading researchers and clinicians
- Special Sessions: Interactive discussions with people living with Parkinson's
- Workshops: Skill-building and educational sessions
- Poster Sessions: Research presentations from around the world
- Exhibition: Industry and nonprofit organization booths
- Gene therapy approaches for PD
- Cell replacement therapy updates
- Novel pharmacological targets
- Device-assisted therapies
¶ Biomarker and Diagnostic Development
- Digital biomarker validation
- Skin biopsy advancements
- Olfactory testing standardization
- Genetic testing integration
¶ Understanding Non-Motor Symptoms
- Sleep disorders in PD
- Cognitive dysfunction
- Autonomic dysfunction
- Neuropsychiatric symptoms
Major pharmaceutical and device companies at WPC:
- AbbVie — Dopamine agonist programs
- Boston Scientific — Deep brain stimulation
- Medtronic — Neurostimulation devices
- UCB Pharma — Parkinson's pipeline
- Novartis — Gene therapy research
- Denali Therapeutics — LRRK2 and other programs
- Michael J. Fox Foundation
- Parkinson's Foundation
- Parkinson's UK
- European Parkinson's Disease Association
- Tremor management
- Gait and balance
- Dyskinesia treatment
- Motor fluctuations
- Depression and anxiety
- Sleep disorders
- Constipation
- Cognitive changes
- Gene therapy vectors
- Alpha-synuclein targeting
- Mitochondrial protectants
- Neuroinflammation modulators
This conference page links to the following NeuroWiki content:
| Year |
Location |
Key Themes |
| 2022 |
Barcelona |
Patient-centric care, gene therapy |
| 2019 |
Kyoto |
Alpha-synuclein, LRRK2 |
| 2016 |
Portland |
Patient involvement, multidisciplinary care |
WPC has been instrumental in: